<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, clinical manifestations, diagnosis, and treatment of &lt;i&gt;Haemophilus influenzae&lt;/i&gt;</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia Yeh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Haemophilus influenzae</em> are pleomorphic gram-negative rods that commonly colonize and infect the human respiratory tract. The <em>H. influenzae</em> species is divided into typeable (encapsulated) and nontypeable (unencapsulated) strains.</p><p>Among typeable strains, <em>H. influenzae</em> serotype b (Hib) is the most virulent. In areas of the world where Hib vaccination is not widespread, Hib is a leading of cause of meningitis and epiglottitis in children and pneumonia in adults. By contrast, in areas where vaccination is routine, the prevalence of Hib has declined, while the prevalence of nontypeable <em>H. influenzae</em> has increased. Nontypeable strains tend to be less virulent than Hib and most commonly cause otitis media and infections of the respiratory tract such as acute rhinosinusitis, acute bronchitis, acute exacerbations of chronic obstructive pulmonary disease, and pneumonia.</p><p>The bacteriology, epidemiology, and treatment of <em>H. influenzae</em> are reviewed here. Postexposure chemoprophylaxis and <em>H. influenzae</em> type b vaccination are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY</span></p><p class="headingAnchor" id="H386228882"><span class="h2">Taxonomy</span><span class="headingEndMark"> — </span>There are six typeable (encapsulated) strains of <em>H. influenzae</em> and multiple nontypeable (nonencapsulated) biotypes [<a href="#rid1">1,2</a>]. Typeable strains are classified serologically (a through f) based on distinct polysaccharide antigens on their capsular surfaces. Type b is the most prominent strain, historically accounting for the majority of cases of invasive disease.</p><p>Nontypeable strains are classified into biotypes based upon the presence or absence of indole, urease, and ornithine decarboxylase. Nontypeable strains are genetically heterogenous and differ in their pathogenic potential [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H2888280334"><span class="h2">Pathogen</span><span class="headingEndMark"> — </span><em>H. influenzae</em> are small, pleomorphic gram-negative rods that are oxidase positive, facultatively anaerobic, and nonmotile. In clinical specimens obtained from patients who have received beta-lactam antibiotics, <em>H. influenzae</em> can appear as filamentous rods.</p><p>In vitro growth requires a CO<sub>2</sub>-enriched atmosphere, <a class="drug drug_general" data-topicid="8970" href="/z/d/drug information/8970.html" rel="external">hemin</a> (factor X), and nicotinamide adenine dinucleotide (NAD; factor V); therefore, isolation from clinical specimens on solid medium requires the use of chocolate agar or other X and V factor supplemented media. <em>H. influenzae</em> appear as transparent or slightly opaque colonies on solid media.</p><p class="headingAnchor" id="H2932228763"><span class="h2">Transmission</span><span class="headingEndMark"> — </span><em>H. influenzae</em> is<em> </em>primarily spread from person to person via airborne droplets or by direct contact with respiratory secretions from infected or colonized individuals [<a href="#rid2">2</a>]. Humans are the only known reservoir for <em>H. influenzae.</em> The nasopharynx is the most common site of long-term colonization. Rarely, <em>H. influenzae</em> can colonize the lower genital tract; direct contact with genital secretions or aspiration of amniotic fluid can lead to infection in neonates [<a href="#rid3">3,4</a>]. The incubation period is unknown [<a href="#rid5">5</a>].</p><p>Before widespread immunization, the secondary attack rate with encapsulated type B strains among children who were household contacts of an index case was 0.3 percent, which is 500-fold higher than the age-adjusted risk in the general population [<a href="#rid6">6</a>]. This risk of secondary infection increased inversely with age; children &lt;4 years of age were at greatest risk, and clinical disease was most likely in the first 30 days after exposure to the index case [<a href="#rid7">7-13</a>].</p><p class="headingAnchor" id="H201919062"><span class="h1">PATHOGENESIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colonization</strong> – Colonization of the respiratory mucosa is the first step in pathogenesis for most infections caused by typeable and nontypeable <em>H. influenzae</em>. The outer membrane of <em>H. influenzae</em> contains several adhesins that mediate attachment to the respiratory tract epithelium including pili, fimbriae, high molecular weight factors (HMW1 and HMW2), and Hia (homologous to the pertussis hemagglutinin) [<a href="#rid14">14-18</a>]. Bacterial cell wall lipoproteins (including lipooligosaccharide [LOS]) impair ciliary function, hindering clearance of <em>H. influenzae </em>from the respiratory tract, and also induce local inflammation.</p><p></p><p class="bulletIndent1">Colonization is a dynamic process, with new strains routinely transiting through the respiratory mucosa [<a href="#rid19">19-21</a>]. In some instances, acquisition of a new strain alone can be sufficient to cause symptomatic respiratory tract infection (eg, a cold in a child or a chronic obstructive pulmonary disease exacerbation in an adult). Other infections, such as acute otitis media or rhinosinusitis, result from direct extension along the respiratory mucosa to a new site. Direct extension is likely facilitated by a high density of colonizing bacteria coupled with their ability to form biofilms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucosal infection</strong> – Infection at mucosal surfaces is further facilitated by bacterial production of immunoglobulin (Ig)A proteases, which cleave IgA at its hinge region thereby inhibiting agglutination, bacterial binding, and opsonization [<a href="#rid22">22-24</a>]. Nontypeable strains also evade the immune system by surviving intracellularly in respiratory epithelial cells and macrophages, providing a site for persistent colonization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive infection</strong> – Tissue invasion is also a critical pathogenic feature. Invasive disease refers to infection that extends beyond the respiratory tract. Invasive clinical syndromes caused by <em>H. influenzae</em> include meningitis, bacteremia, epiglottitis, septic arthritis, cellulitis, purulent pericarditis, endocarditis, and osteomyelitis [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Most invasive infections are caused <em>by H. influenzae </em>type b (Hib). The type b capsule contains polyribitol ribose phosphate, a potent virulence factor, which enables invasion of local tissue, the bloodstream, and, in some instances, the central nervous system [<a href="#rid21">21,26</a>]. The other capsular serotypes have a different glycosylation pattern and less frequently cause invasive disease compared with Hib. Nontypeable strains are less invasive but can access the vascular system by transmural migration through epithelial tight junctions or by an independent intercellular mechanism [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H2620015904"><span class="h1">IMMUNITY</span><span class="headingEndMark"> — </span>Innate and acquired humoral immunity play important roles in host defense. Structural defenses such as mucociliary function are first-line defenses. The mucociliary apparatus promotes clearance and prevents spread to the lower respiratory tract. When impaired (eg, cystic fibrosis, chronic obstructive pulmonary disease, other structural lung diseases), rates of lower respiratory tract colonization and infection rise.</p><p><em>H. influenzae</em> lipooligosaccharide activates the alternative complement pathway, stimulating C3b opsonization and subsequent bacterial phagocytosis. The importance of early complement in immune control is evinced by the observation that individuals with early complement deficiency are at increased risk for <em>H. influenzae</em> infections [<a href="#rid28">28</a>].</p><p>Mechanisms for adaptive immune control of typeable and nontypeable <em>H. influenzae </em>differ. The antibody response to nontypeable strains is typically strong and bactericidal [<a href="#rid29">29</a>]. Bactericidal activity is mediated by the membrane-attack complex of the classical (antibody-mediated) complement pathway. In animal models, immunization with one nontypeable strain appears to provide protection against invasive infection with other nontypeable strains. This finding may explain why nontypeable strains are primarily mucosal pathogens that rarely spread beyond the respiratory tract. By contrast, typeable strains have a dense polysaccharide capsule, which renders greater resistance to complement-mediated killing and phagocytosis, thus enabling systemic infection.</p><p>Protection against invasive <em>H. influenzae </em>type b (Hib) infections is mediated by antibodies to the type b capsular polysaccharide polyribitol ribose phosphate (PRP). Newborns are protected against Hib by maternal antibodies, but they are susceptible to infection with nontypeable (unencapsulated) strains [<a href="#rid30">30</a>]. Breastfeeding affords some protection against <em>H. influenzae</em> [<a href="#rid31">31</a>]. As maternal antibody levels wane, children become susceptible to invasive Hib infection from around age 3 months to 3 years. Conjugate vaccines targeting PRP are highly effective at reducing systemic infections in young children and subsequently infections in the population via herd immunity.</p><p>Prior to routine use of conjugate vaccines, children older than three years of age progressively gained protection against invasive disease with repeated exposure and subsequent nasopharyngeal colonization. The decline in individual serum anti-Hib antibody levels observed since introduction of Hib vaccination suggests that ongoing antigen exposure in the setting of Hib colonization may play a role Hib immunity [<a href="#rid30">30,32</a>].</p><p class="headingAnchor" id="H7"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1773051680"><span class="h2">Colonization</span></p><p class="headingAnchor" id="H1333416180"><span class="h3">Nasopharyngeal colonization</span><span class="headingEndMark"> — </span><em>H. influenzae</em>, particularly nontypeab<em>le H. influenzae</em> (NTHi), is a common commensal of the nasopharynx [<a href="#rid33">33-35</a>]. Approximately 20 percent of infants are colonized in the first year of life, and more than one half of children are colonized by age 5 years [<a href="#rid35">35</a>]. Children may simultaneously be colonized by multiple distinct strains and colonizing strains may change over time [<a href="#rid6">6,36-38</a>]. Colonization can persist for months, during which intercurrent upper respiratory infection may promote invasive disease and transmission to close contacts [<a href="#rid6">6,39-41</a>]. Colonization persists throughout adulthood [<a href="#rid42">42</a>].</p><p class="bulletIndent1">The use of conjugate <em>H. influenzae</em> serotype b (Hib) vaccines in infancy has been associated with reduced prevalence of nasopharyngeal Hib carriage (from approximately 2 to 7 percent in the prevaccine era to &lt;1 percent in the postvaccine era in the United States [<a href="#rid43">43,44</a>]). Reduction in carriage appears to be influenced by the number and type of Hib immunizations and the time elapsed since the last immunization [<a href="#rid45">45</a>]. The differences in international immunization schedules may result in differing carriage and disease patterns.</p><p></p><p class="headingAnchor" id="H1071621684"><span class="h3">Genital tract colonization</span><span class="headingEndMark"> — </span>NTHi can also colonize the female genital tract and cause locally invasive disease, such as endometritis, amnionitis, or Bartholin gland abscess, with or without accompanying bacteremia [<a href="#rid3">3,46</a>]. (See <a class="local">'Nontypeable H. influenzae'</a> below.)</p><p class="headingAnchor" id="H3883959371"><span class="h2">Hib invasive disease</span><span class="headingEndMark"> — </span>Universal immunization of infants against <em>H. influenzae</em> type b (Hib), which began in the early 1990s and is practiced in nearly all developed countries [<a href="#rid47">47</a>], has been associated with dramatic declines in the incidence of invasive Hib disease in children &lt;5 years of age [<a href="#rid48">48-50</a>].</p><p>As the number of countries using Hib vaccines increased between 2000 and 2015, the estimated number of worldwide cases of severe Hib disease in children &lt;5 years of age declined from &gt;8 million to 340,000 [<a href="#rid48">48,49</a>]. Estimated Hib-related deaths among children &lt;5 years of age also declined from 371,000 to &lt;30,000.</p><p>Based on surveillance conducted in the United States, the incidence of invasive Hib disease in children &lt;5 years of age declined from &gt;20 cases per 100,000 children in the prevaccine era to ≤0.25 cases per 100,000 children during 2000 to 2012 (<a class="graphic graphic_figure graphicRef94439" href="/z/d/graphic/94439.html" rel="external">figure 1</a>) [<a href="#rid50">50</a>]. In 2018, the reported incidence in children &lt;5 years of age was 0.08 per 100,000 children [<a href="#rid51">51</a>]. Between 2009 and 2015, the incidence of invasive Hib disease in children ≥5 years of age and adults was &lt;0.05 per 100,000 population [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H624824504"><span class="h2">Hia invasive disease</span><span class="headingEndMark"> — </span>Recent surveillance data has demonstrated <em>H. influenzae</em> type a (Hia) has increased since 2008 by an average of 11.1 percent annually. Hia can cause invasive disease similar to Hib. The estimated annual incidence is 0.10 cases/100,000 persons per year, with the highest incidence among American Indian and Alaska Native children (8.29 cases/100,000 persons per year among those &lt;5 years of age), with the highest incidence among Alaska Native children &lt;1 year of age of 24.7 cases/100,000 persons per year. Currently, no vaccine against Hia exists [<a href="#rid53">53</a>]. </p><p class="headingAnchor" id="H1825467775"><span class="h2">Nontypeable H. influenzae and non-b encapsulated serotypes</span><span class="headingEndMark"> — </span>Although the overall incidence of invasive disease due to NTHi and non-b encapsulated serotypes remains low, since 2000, there has been an increased recognition of invasive disease due to NTHi and non-b serotypes (eg, serotypes a, e, and f) in children and adults [<a href="#rid52">52-63</a>].</p><p>NTHi causes the majority of invasive <em>H. influenzae</em> infections in all age groups. During the period between 2009 and 2015, the incidence of invasive disease due to NTHi was 1.22 per 100,000 population and the incidence of invasive disease due to non-b serotypes was 0.45 per 100,000 population in the United States [<a href="#rid52">52</a>].</p><p>NTHi and non-b encapsulated serotype invasive disease predominantly occurs in the oldest and youngest age groups. During 2009 to 2015, the incidence of NTHi invasive disease was 4.99 per 100,000 adults ≥65 years of age and 5.63 per 100,000 infants &lt;1 year of age; many of the cases in infants occurred in those who were &lt;1 month of age, preterm, or low birth weight [<a href="#rid52">52</a>]. The incidence of non-b encapsulated serotype invasive disease was 1.27 per 100,000 adults ≥65 years and 2.53 per 100,000 infants &lt;1 year of age.</p><p>Similar trends of increasing invasive disease due to NTHi and non-b serotypes have been noted in other countries [<a href="#rid56">56,57,64</a>]. It is unclear whether these changes are related to vaccine-mediated strain replacement, improved bacterial detection and serotyping, increased virulence of NTHi strains, or demographic changes [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for invasive Hib infection include [<a href="#rid50">50,65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;5 years and incomplete Hib immunization</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional or anatomic asplenia, including sickle cell disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin deficiency and other deficits in humoral immunity (see  <a class="medical medical_review" href="/z/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early component complement deficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematopoietic cell transplant recipient</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy or radiation therapy for malignancy [<a href="#rid65">65</a>]</p><p></p><p>Native American children (including Alaska Native children, Indigenous (Aboriginal) children in Canada, and Aboriginal Australian children) appear to be at increased risk for invasive <em>H. influenzae</em> disease compared with the general population [<a href="#rid52">52,66-68</a>]. </p><p>In adults, typeable and nontypeable <em>H. influenzae</em> disease has been associated with underlying conditions such as structural lung disease (eg, cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis), smoking, alcoholism, pregnancy, and older age [<a href="#rid52">52,69-72</a>]. Socioeconomic factors that increase the risk of <em>H. influenzae</em> disease include crowding, incomplete Hib immunization, and daycare attendance [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H261961971"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3160566230"><span class="h2">Hib and non-b encapsulated serotypes</span><span class="headingEndMark"> — </span>In the post-<em>H. influenzae</em> type b (Hib) conjugate vaccine era, serious Hib infections are rare [<a href="#rid73">73,74</a>]. Invasive disease occurs predominantly in infants and young children who are unimmunized or incompletely immunized against Hib and in older children and adults with immune-compromising conditions [<a href="#rid50">50,75</a>].</p><p>Hib can cause a number of clinical syndromes, including [<a href="#rid5">5,76,77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Meningitis</p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia</p><p class="bulletIndent1"><span class="glyph">●</span>Otitis media</p><p class="bulletIndent1"><span class="glyph">●</span>Epiglottitis</p><p class="bulletIndent1"><span class="glyph">●</span>Uvulitis</p><p class="bulletIndent1"><span class="glyph">●</span>Community-acquired pneumonia and empyema</p><p class="bulletIndent1"><span class="glyph">●</span>Exacerbations of chronic obstructive pulmonary disease (COPD)</p><p class="bulletIndent1"><span class="glyph">●</span>Pericarditis</p><p class="bulletIndent1"><span class="glyph">●</span>Septic arthritis</p><p class="bulletIndent1"><span class="glyph">●</span>Cellulitis, including buccal, preseptal, and orbital cellulitis</p><p></p><p>Less common manifestations include endocarditis, endophthalmitis, osteomyelitis, peritonitis, and necrotizing soft tissue infections [<a href="#rid5">5</a>].</p><p>Non-b serotypes can cause the same clinical syndromes as Hib [<a href="#rid55">55,78-83</a>]. In population- and laboratory-based surveillance of invasive disease caused by serotype a from eight sites in the United States, meningitis was the most common manifestation in children &lt;1 year old, whereas bacteremic pneumonia was the most common manifestation in adults ≥50 years old [<a href="#rid78">78</a>]. </p><p>Although infections due to invasive Hib and non-b serotypes are rare, they are associated with substantial mortality. In United States surveillance between 2009 and 2015, the case-fatality rate was 4 percent for invasive Hib disease and 11 percent for non-b serotype invasive disease.</p><p class="headingAnchor" id="H1159655715"><span class="h2">Nontypeable H. influenzae</span><span class="headingEndMark"> — </span>Nontypeable <em>H. influenzae</em> (NTHi) strains typically cause noninvasive mucosal infections in older children and adults, usually as a result of local spread of organisms from the nasopharynx [<a href="#rid64">64,84</a>]. It is an important cause of sinusitis, acute otitis media, conjunctivitis, chronic obstructive pulmonary disease exacerbations, and community-acquired pneumonia in children and adults [<a href="#rid34">34,85-87</a>].</p><p>Rarely, NTHi causes locally invasive genital tract infections (eg, endometritis, amnionitis, Bartholin gland abscess) with or without accompanying bacteremia [<a href="#rid46">46</a>].</p><p>In the post-Hib conjugate vaccine era, NTHi has also been identified as a cause of invasive infections (eg, bacteremia, meningitis, sepsis), particularly in older adults and young infants [<a href="#rid34">34,50,52</a>]. Among pregnant women, infection with NTHi has been associated with preterm birth, fetal loss, and neonatal sepsis [<a href="#rid70">70,88,89</a>].</p><p>Invasive NTHi infection is associated with increased mortality. In United States surveillance between 2009 and 2015, the case-fatality rate for invasive NTHi infection was 16 percent [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H852766455"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3951870569"><span class="h2">Approach to testing</span></p><p class="headingAnchor" id="H3967135812"><span class="h3">Respiratory infections</span><span class="headingEndMark"> — </span>For most respiratory infections caused by <em>H. influenzae</em> (typeable and nontypeable), a diagnosis is usually made based on the characteristic signs and symptoms of the particular syndrome (eg, acute otitis media, conjunctivitis, exacerbation of chronic obstructive pulmonary disease).</p><p class="bulletIndent1">An etiologic diagnosis usually is not sought in uncomplicated noninvasive respiratory tract infections because empiric antimicrobial therapy typically includes activity against <em>H. influenzae</em> and isolation of <em>H. influenzae</em> from respiratory tract specimens does not differentiate colonization from infection. (See <a class="local">'Empiric treatment'</a> below and <a class="local">'Colonization'</a> above.)</p><p></p><p class="headingAnchor" id="H695116256"><span class="h3">Invasive infections</span><span class="headingEndMark"> — </span>For patients with invasive disease (eg, bacteremia, meningitis, septic arthritis), the diagnosis of <em>H. influenzae </em>infection is confirmed by detection of <em>H. influenzae</em> through traditional culture or polymerase chain reaction (PCR)-based assays [<a href="#rid90">90,91</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Culture</strong> – Culture is highly specific for <em>H. influenzae</em> but may have poor sensitivity in patients who have received antibiotics or if specimens have not been handled properly [<a href="#rid90">90</a>]. Culture permits testing of isolates for beta-lactamase activity as a predictor of <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> resistance; in addition, isolates may be examined for resistance to other antimicrobials of potential clinical use. If necessary for epidemiologic investigations or decisions regarding chemoprophylaxis for Hib, isolates can be sent to a public health laboratory for serotyping. </p><p></p><p class="bulletIndent1">If available, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is another method for identifying and typing<em> H. influenzae </em>with high sensitivity and specificity [<a href="#rid90">90,91</a>]. Turn-around time is shorter than for traditional serotyping methods. MALDI-TOF cannot differentiate between typeable and nontypeable <em>H. influenzae </em>and does not permit susceptibility testing.</p><p></p><p class="bulletIndent1">Culture of specimens for specific clinical syndromes is discussed in the topic reviews related to those syndrome (eg, meningitis, bacteremia, septic arthritis, complicated pneumonia). Examples of appropriate specimens include cerebrospinal fluid, blood, and synovial fluid [<a href="#rid91">91</a>]. The microbiologic characteristics and growth requirements for<em> H. influenzae</em> are described above. (See <a class="local">'Pathogen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCR-based assays</strong> – PCR-based assays have high sensitivity and specificity and rapid turn-around time and can be used in patients who received antibiotics before the specimen was obtained [<a href="#rid90">90</a>]. Some PCR assays can differentiate between serotypes, but they do not permit testing for antimicrobial resistance.</p><p></p><p class="bulletIndent1">Commercial multiplex PCR assays are available for bloodstream, respiratory tract, and central nervous system (CNS) infections. Most of these assays do not identify serotype. </p><p></p><p class="bulletIndent1">When <em>H. influenzae </em>is identified by PCR, laboratories should perform a culture or send a sample to a state lab for culture to determine serotype and antimicrobial susceptibility and to allow for more accurate surveillance [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1">Molecular testing for CNS infections is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1278.html" rel="external">"Molecular diagnosis of central nervous system infections"</a>.)</p><p></p><p class="headingAnchor" id="H245076854"><span class="h2">Susceptibility testing</span><span class="headingEndMark"> — </span>Most clinical laboratories perform a rapid assay for beta-lactamase production, which is the main mechanism of antimicrobial resistance. When the assay is positive, isolates can be considered to be resistant to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, penicillin, and first-generation cephalosporins but susceptible to combination beta-lactam-beta-lactamase inhibitors (eg, <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>), extended-spectrum cephalosporins, and carbapenems. A negative beta-lactamase assay indicates that the isolate is likely susceptible to ampicillin but does not fully exclude the possibility of ampicillin resistance, which is less commonly mediated by other mechanisms (eg, alterations in cell-wall penicillin-binding proteins). Additional susceptibility testing is not widely available but is generally unnecessary because antimicrobial resistance patterns are predictable.</p><p class="headingAnchor" id="H3805255409"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1115106976"><span class="h2">Empiric treatment</span><span class="headingEndMark"> — </span>Most infections caused by <em>H. influenzae</em> are treated empirically. In general, empiric regimens are designed to include an antibiotic that treats <em>H. influenzae</em>. Antibiotics that have activity against <em>H. influenzae</em> include beta-lactams (eg, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, or second- and third-generation cephalosporins), fluoroquinolones, macrolides, and tetracyclines.</p><p>Beta-lactams are generally preferred. <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">Amoxicillin-clavulanate</a> is a commonly used empiric treatment option for localized and non-life-threatening infections, such as otitis media, sinusitis, and acute exacerbations of chronic obstructive pulmonary disease. In patients with systemic infections, such as bacteremia or meningitis, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> is the treatment of choice. (See <a class="local">'Ampicillin resistance'</a> below.)</p><p>Empiric regimens for specific syndromes caused by <em>H. influenzae</em> are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Community-acquired pneumonia in adults (see  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Community-acquired pneumonia in children (see  <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">"Community-acquired pneumonia in children: Outpatient treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial meningitis (see  <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epiglottitis (see  <a class="medical medical_review" href="/z/d/html/6076.html" rel="external">"Epiglottitis (supraglottitis): Management", section on 'Antimicrobial therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease exacerbation (see  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease", section on 'Empiric antibacterial treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinusitis (see  <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment", section on 'Antibiotics'</a> and  <a class="medical medical_review" href="/z/d/html/5999.html" rel="external">"Acute bacterial rhinosinusitis in children: Microbiology and management", section on 'Empiric antibiotics'</a>)</p><p></p><p class="headingAnchor" id="H2693784799"><span class="h2">Directed treatment</span><span class="headingEndMark"> — </span>For patients with microbiologically diagnosed <em>H. influenzae</em> infections, antibiotic selection depends on the site and severity of infection and, when available, the results of laboratory susceptibility tests:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with mild to moderate infections treated in the outpatient setting (eg, chronic obstructive pulmonary disease exacerbations, pneumonia), we generally use an oral beta-lactam (such as <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>) or an oral second- or third-generation cephalosporin (such as <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a>, <a class="drug drug_general" data-topicid="8602" href="/z/d/drug information/8602.html" rel="external">cefdinir</a>, <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a>, or <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe infections (eg, meningitis, epiglottitis, bacteremia, or other respiratory tract infections requiring hospitalization), we typically use an intravenous third-generation cephalosporin such as <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>. Because of the severity of such infections, we avoid treatment with <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> unless the infecting pathogen has been shown to be beta-lactamase negative.</p><p></p><p class="bulletIndent1">For children with known or suspected <em>H. influenzae </em>meningitis, giving adjunctive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> at the time antibiotics are started (or just before) appears to improve outcomes. (See  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications"</a>.)</p><p></p><p>Because antimicrobial susceptibility patterns vary regionally and susceptibility testing is not routinely available, modifications to this approach may be needed, particularly in areas where <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> resistance is high. (See <a class="local">'Ampicillin resistance'</a> below.)</p><p>Alternative options to cephalosporins include fluoroquinolones, tetracyclines, and carbapenems.</p><p class="headingAnchor" id="H151730711"><span class="h2">Ampicillin resistance</span><span class="headingEndMark"> — </span>The production of a beta-lactamase, which confers resistance to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, and penicillin, is the major mechanism of antimicrobial resistance among typeable and nontypeable <em>H. influenzae</em> strains. In the United States, approximately 25 to 28 percent of <em>H. influenzae </em>strains are estimated to produce beta-lactamase [<a href="#rid93">93,94</a>]. Beta-lactamase-producing strains typically remain susceptible to beta-lactam-beta-lactamase inhibitor combinations (ie, <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>), second- and third-generation cephalosporins, and carbapenems.</p><p>Infrequently, resistance to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> can be mediated by mechanisms other than beta-lactamase production (eg, alterations in penicillin-binding proteins) [<a href="#rid95">95</a>]. Isolates with this resistance pattern are termed beta-lactamase negative ampicillin resistant (BLNAR). Such isolates have been most commonly described in Asia [<a href="#rid57">57,95-101</a>]. While their clinical significance is unknown, most reported BLNAR isolates appear to be susceptible to <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid101">101</a>].</p><p>Resistance rates to most other antibiotics (ie, fluoroquinolones, tetracyclines) are generally low (ie, approximately 1 to 5 percent) [<a href="#rid93">93,96,102-105</a>]. <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">Trimethoprim</a> and <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> may be exceptions [<a href="#rid93">93</a>]; <em>H. influenzae </em>are not reliably susceptible to these agents; thus, they are not used for treatment.</p><p class="headingAnchor" id="H522517288"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Because <em>H. influenzae </em>is transmitted by respiratory droplets and direct contact with secretions, respiratory and hand hygiene are key to preventing spread. The United States Centers for Disease Control and Prevention recommend both standard and droplet precautions for hospitalized patients with invasive <em>H. influenzae</em> infections (ie, pneumonia in children, meningitis, epiglottitis) [<a href="#rid106">106</a>]. These precautions can generally be discontinued 24 hours after effective therapy has been given.</p><p>Postexposure chemoprophylaxis for at-risk patients and <em>H. influenzae</em> type b vaccination are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection"</a>.)</p><p class="headingAnchor" id="H1053902167"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology </strong>–<strong> </strong><em>Haemophilus influenzae</em> are pleomorphic gram-negative bacilli that commonly colonize and infect the respiratory tract. Humans are the only known reservoir, and <em>H. influenzae </em>are<em> </em>primarily spread from person to person via airborne droplets or by direct contact with respiratory secretions. (See <a class="local">'Introduction'</a> above and <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Encapsulated and unencapsulated strains </strong>– The <em>H. influenzae</em> species is divided into typeable (encapsulated) and nontypeable (unencapsulated) strains. Among typeable strains, <em>H. influenzae</em> type b (Hib) is the most virulent. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence </strong>– In the post-Hib conjugate vaccine era, invasive Hib disease in children &lt;5 years of age is rare. Although the overall incidence of invasive disease due to nontypeable <em>H. influenzae</em> (NTHi) and non-b serotypes remains low, there has been an increase in the identification of invasive disease due to NTHi and non-b serotypes in children and adults, predominantly affecting adults ≥65 years and infants &lt;1 month of age. (See <a class="local">'Hib invasive disease'</a> above and <a class="local">'Nontypeable H. influenzae and non-b encapsulated serotypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– Risk factors for invasive Hib infection include age &lt;5 years and incomplete Hib immunization, functional or anatomic asplenia (including sickle cell disease), HIV infection, immunoglobulin deficiency and other deficits in humoral immunity, early component complement deficiency, hematopoietic cell transplant recipient, and chemotherapy or radiation therapy for malignancy. In adults, typeable and nontypeable <em>H. influenzae</em> disease has been associated with underlying conditions such as structural lung disease (eg, cystic fibrosis, chronic obstructive pulmonary disease [COPD], bronchiectasis), smoking, alcoholism, pregnancy, and older age. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Encapsulated strains </strong>– Clinical manifestations of Hib and non-b serotypes include meningitis, bacteremia, otitis media, epiglottitis, community-acquired pneumonia and empyema, pericarditis, septic arthritis, and cellulitis. Invasive Hib and non-b serotype disease is associated with increased mortality. (See <a class="local">'Hib and non-b encapsulated serotypes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unencapsulated strains </strong>– NTHi typically causes noninvasive mucosal infections in older children and adults. It is an important cause of sinusitis, acute otitis media, conjunctivitis, COPD exacerbations, and community-acquired pneumonia in children and adults. In the post-Hib conjugate vaccine era, NTHi has also been identified as a cause of invasive infections (eg, bacteremia, meningitis, sepsis). Invasive NTHi infection is associated with increased mortality. (See <a class="local">'Nontypeable H. influenzae'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>For most respiratory infections caused by <em>H. influenzae</em>, a diagnosis is usually made clinically; an etiologic diagnosis usually is not sought because empiric antimicrobial therapy typically includes activity against <em>H. influenzae</em>. For patients with invasive disease, the diagnosis of <em>H. influenzae</em> is confirmed by detection of <em>H. influenzae</em> through traditional culture or polymerase chain reaction-based assays. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Beta-lactams preferred</strong> – Beta-lactam antibiotics (ie, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, or second- and third-generation cephalosporins) are preferred for treatment. Other antibiotics with activity against <em>H. influenzae</em> include fluoroquinolones, tetracyclines, and carbapenems. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe infections and </strong><strong>ampicillin</strong><strong> resistance </strong>–<strong> </strong>Because of potential <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> resistance, we generally use intravenous third-generation cephalosporins (eg, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>) when treating severe infections such as meningitis, epiglottitis, and bacteremia. (See <a class="local">'Directed treatment'</a> above and <a class="local">'Ampicillin resistance'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">St Geme JW 3rd, Takala A, Esko E, Falkow S. Evidence for capsule gene sequences among pharyngeal isolates of nontypeable Haemophilus influenzae. J Infect Dis 1994; 169:337.</a></li><li class="breakAll">Murphy TF. Haemophilus species, Including H. influenzae and H. ducreyi (chancroid). In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th ed, Bennett JE, Dolin R, Blaser MJ (Eds), Elsevier, Philadelphia 2015. p.2575.</li><li><a class="nounderline abstract_t">Cardines R, Daprai L, Giufrè M, et al. Genital carriage of the genus Haemophilus in pregnancy: species distribution and antibiotic susceptibility. J Med Microbiol 2015; 64:724.</a></li><li><a class="nounderline abstract_t">Ault KA. Vaginal flora as the source for neonatal early onset Haemophilus influenzae sepsis. Pediatr Infect Dis J 1994; 13:243.</a></li><li class="breakAll">American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.345.</li><li><a class="nounderline abstract_t">Mäkelä PH, Takala AK, Peltola H, Eskola J. Epidemiology of invasive Haemophilus influenzae type b disease. J Infect Dis 1992; 165 Suppl 1:S2.</a></li><li><a class="nounderline abstract_t">Ward JI, Fraser DW, Baraff LJ, Plikaytis BD. Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med 1979; 301:122.</a></li><li><a class="nounderline abstract_t">Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. Recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42:1.</a></li><li><a class="nounderline abstract_t">Band JD, Fraser DW, Ajello G. Prevention of Hemophilus influenzae type b disease. JAMA 1984; 251:2381.</a></li><li><a class="nounderline abstract_t">Fleming DW, Leibenhaut MH, Albanes D, et al. Secondary Haemophilus influenzae type b in day-care facilities. Risk factors and prevention. JAMA 1985; 254:509.</a></li><li><a class="nounderline abstract_t">Makintubee S, Istre GR, Ward JI. Transmission of invasive Haemophilus influenzae type b disease in day care settings. J Pediatr 1987; 111:180.</a></li><li><a class="nounderline abstract_t">Osterholm MT, Pierson LM, White KE, et al. The risk of subsequent transmission of Hemophilus influenzae type B disease among children in day care. Results of a two-year statewide prospective surveillance and contact survey. N Engl J Med 1987; 316:1.</a></li><li><a class="nounderline abstract_t">Murphy TV, Clements JF, Breedlove JA, et al. Risk of subsequent disease among day-care contacts of patients with systemic Hemophilus influenzae type B disease. N Engl J Med 1987; 316:5.</a></li><li><a class="nounderline abstract_t">Rao VK, Krasan GP, Hendrixson DR, et al. Molecular determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae. FEMS Microbiol Rev 1999; 23:99.</a></li><li><a class="nounderline abstract_t">Krasan GP, Cutter D, Block SL, St Geme JW 3rd. Adhesin expression in matched nasopharyngeal and middle ear isolates of nontypeable Haemophilus influenzae from children with acute otitis media. Infect Immun 1999; 67:449.</a></li><li><a class="nounderline abstract_t">Kubiet M, Ramphal R, Weber A, Smith A. Pilus-mediated adherence of Haemophilus influenzae to human respiratory mucins. Infect Immun 2000; 68:3362.</a></li><li><a class="nounderline abstract_t">St Geme JW 3rd. Insights into the mechanism of respiratory tract colonization by nontypable Haemophilus influenzae. Pediatr Infect Dis J 1997; 16:931.</a></li><li><a class="nounderline abstract_t">Langereis JD, de Jonge MI. Unraveling Haemophilus influenzae virulence mechanisms enable discovery of new targets for antimicrobials and vaccines. Curr Opin Infect Dis 2020; 33:231.</a></li><li><a class="nounderline abstract_t">Thors V, Christensen H, Morales-Aza B, et al. High-density Bacterial Nasal Carriage in Children Is Transient and Associated With Respiratory Viral Infections-Implications for Transmission Dynamics. Pediatr Infect Dis J 2019; 38:533.</a></li><li><a class="nounderline abstract_t">Su YC, Jalalvand F, Thegerström J, Riesbeck K. The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable Haemophilus influenzae. Front Immunol 2018; 9:2530.</a></li><li><a class="nounderline abstract_t">King P. Haemophilus influenzae and the lung (Haemophilus and the lung). Clin Transl Med 2012; 1:10.</a></li><li><a class="nounderline abstract_t">Whisnant JK, Rogentine GN, Mann DL, Robbins JB. Human cell-surface structures related to Haemophilus influenzae type B disease. Lancet 1971; 2:895.</a></li><li><a class="nounderline abstract_t">Plaut AG. The IgA1 proteases of pathogenic bacteria. Annu Rev Microbiol 1983; 37:603.</a></li><li><a class="nounderline abstract_t">Murphy TF, Kirkham C, Jones MM, et al. Expression of IgA Proteases by Haemophilus influenzae in the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease. J Infect Dis 2015; 212:1798.</a></li><li class="breakAll">Oliver SE. Haemophilus influenzae invasive disease. In: Manual for the Surveillance of Vaccine-Preventable Diseases. Roush SE, Baldy LM, Kirkconnell Hall MA. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/vaccines/pubs/surv-manual/ (Accessed on November 06, 2019).</li><li><a class="nounderline abstract_t">Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J Clin Microbiol 2011; 49:3728.</a></li><li><a class="nounderline abstract_t">Clementi CF, Håkansson AP, Murphy TF. Internalization and trafficking of nontypeable Haemophilus influenzae in human respiratory epithelial cells and roles of IgA1 proteases for optimal invasion and persistence. Infect Immun 2014; 82:433.</a></li><li><a class="nounderline abstract_t">Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359.</a></li><li><a class="nounderline abstract_t">King PT, Ngui J, Gunawardena D, et al. Systemic humoral immunity to non-typeable Haemophilus influenzae. Clin Exp Immunol 2008; 153:376.</a></li><li><a class="nounderline abstract_t">Falla TJ, Dobson SR, Crook DW, et al. Population-based study of non-typable Haemophilus influenzae invasive disease in children and neonates. Lancet 1993; 341:851.</a></li><li><a class="nounderline abstract_t">Petersen GM, Silimperi DR, Chiu CY, Ward JI. Effects of age, breast feeding, and household structure on Haemophilus influenzae type b disease risk and antibody acquisition in Alaskan Eskimos. Am J Epidemiol 1991; 134:1212.</a></li><li><a class="nounderline abstract_t">Winkelstein JA, Moxon ER. The role of complement in the host's defense against Haemophilus influenzae. J Infect Dis 1992; 165 Suppl 1:S62.</a></li><li><a class="nounderline abstract_t">St Geme JW 3rd. Molecular and cellular determinants of non-typeable Haemophilus influenzae adherence and invasion. Cell Microbiol 2002; 4:191.</a></li><li><a class="nounderline abstract_t">Murphy TF, Faden H, Bakaletz LO, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J 2009; 28:43.</a></li><li><a class="nounderline abstract_t">Howard AJ, Dunkin KT, Millar GW. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children. Epidemiol Infect 1988; 100:193.</a></li><li><a class="nounderline abstract_t">Spinola SM, Peacock J, Denny FW, et al. Epidemiology of colonization by nontypable Haemophilus influenzae in children: a longitudinal study. J Infect Dis 1986; 154:100.</a></li><li><a class="nounderline abstract_t">Trottier S, Stenberg K, Svanborg-Edén C. Turnover of nontypable Haemophilus influenzae in the nasopharynges of healthy children. J Clin Microbiol 1989; 27:2175.</a></li><li><a class="nounderline abstract_t">Faden H, Duffy L, Williams A, et al. Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis 1995; 172:132.</a></li><li><a class="nounderline abstract_t">Krasinski K, Nelson JD, Butler S, et al. Possible association of mycoplasma and viral respiratory infections with bacterial meningitis. Am J Epidemiol 1987; 125:499.</a></li><li><a class="nounderline abstract_t">Takala AK, Meurman O, Kleemola M, et al. Preceding respiratory infection predisposing for primary and secondary invasive Haemophilus influenzae type b disease. Pediatr Infect Dis J 1993; 12:189.</a></li><li><a class="nounderline abstract_t">DeMuri GP, Gern JE, Eickhoff JC, et al. Dynamics of Bacterial Colonization With Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection. Clin Infect Dis 2018; 66:1045.</a></li><li><a class="nounderline abstract_t">Kuklinska D, Kilian M. Relative proportions of Haemophilus species in the throat of healthy children and adults. Eur J Clin Microbiol 1984; 3:249.</a></li><li><a class="nounderline abstract_t">Mohle-Boetani JC, Ajello G, Breneman E, et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 1993; 12:589.</a></li><li><a class="nounderline abstract_t">Lowther SA, Shinoda N, Juni BA, et al. Haemophilus influenzae type b infection, vaccination, and H. influenzae carriage in children in Minnesota, 2008-2009. Epidemiol Infect 2012; 140:566.</a></li><li><a class="nounderline abstract_t">Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Baker CJ, Quinones FJ, et al. Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen. Rev Infect Dis 1983; 5:123.</a></li><li><a class="nounderline abstract_t">Santosham M. Commentary: The Conquest of Haemophilus influenzae Type B-The Importance of Protecting High-Risk Children. Pediatr Infect Dis J 2018; 37:725.</a></li><li><a class="nounderline abstract_t">Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374:903.</a></li><li><a class="nounderline abstract_t">Wahl B, O'Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018; 6:e744.</a></li><li><a class="nounderline abstract_t">Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2014; 63:1.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report
Emerging Infections Program Network Haemophilus influenzae, 2018. https://www.cdc.gov/abcs/reports-findings/survreports/hib18.pdf (Accessed on June 22, 2021).</li><li><a class="nounderline abstract_t">Soeters HM, Blain A, Pondo T, et al. Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease-United States, 2009-2015. Clin Infect Dis 2018; 67:881.</a></li><li><a class="nounderline abstract_t">Soeters HM, Oliver SE, Plumb ID, et al. Epidemiology of Invasive Haemophilus influenzae Serotype a Disease-United States, 2008-2017. Clin Infect Dis 2021; 73:e371.</a></li><li><a class="nounderline abstract_t">Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010; 28:4073.</a></li><li><a class="nounderline abstract_t">Bender JM, Cox CM, Mottice S, et al. Invasive Haemophilus influenzae disease in Utah children: an 11-year population-based study in the era of conjugate vaccine. Clin Infect Dis 2010; 50:e41.</a></li><li><a class="nounderline abstract_t">Resman F, Ristovski M, Ahl J, et al. Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains. Clin Microbiol Infect 2011; 17:1638.</a></li><li><a class="nounderline abstract_t">Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae Disease, Europe, 1996-2006. Emerg Infect Dis 2010; 16:455.</a></li><li><a class="nounderline abstract_t">Ribeiro GS, Reis JN, Cordeiro SM, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 2003; 187:109.</a></li><li><a class="nounderline abstract_t">Ulanova M, Tsang RSW. Haemophilus influenzae serotype a as a cause of serious invasive infections. Lancet Infect Dis 2014; 14:70.</a></li><li><a class="nounderline abstract_t">Giufrè M, Cardines R, Brigante G, et al. Emergence of Invasive Haemophilus influenzae Type A Disease in Italy. Clin Infect Dis 2017; 64:1626.</a></li><li><a class="nounderline abstract_t">Ladhani SN, Collins S, Vickers A, et al. Invasive Haemophilus influenzae serotype e and f disease, England and Wales. Emerg Infect Dis 2012; 18:725.</a></li><li><a class="nounderline abstract_t">MacNeil JR, Cohn AC, Farley M, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. Clin Infect Dis 2011; 53:1230.</a></li><li><a class="nounderline abstract_t">Collins LF, Havers FP, Tunali A, et al. Invasive Nontypeable Haemophilus influenzae Infection Among Adults With HIV in Metropolitan Atlanta, Georgia, 2008-2018. JAMA 2019; 322:2399.</a></li><li><a class="nounderline abstract_t">Langereis JD, de Jonge MI. Invasive Disease Caused by Nontypeable Haemophilus influenzae. Emerg Infect Dis 2015; 21:1711.</a></li><li><a class="nounderline abstract_t">McNair J, Smith A, Bettinger JA, et al. Invasive Haemophilus Influenzae Type B Infections in Children with Cancer in the Era of Infant HIB Immunization Programs (1991-2014): A Report From the Canadian Immunization Monitoring Program Active. Pediatr Infect Dis J 2018; 37:726.</a></li><li><a class="nounderline abstract_t">Brown VM, Madden S, Kelly L, et al. Invasive Haemophilus influenzae disease caused by non-type b strains in Northwestern Ontario, Canada, 2002-2008. Clin Infect Dis 2009; 49:1240.</a></li><li><a class="nounderline abstract_t">Cleland G, Leung C, Wan Sai Cheong J, et al. Paediatric invasive Haemophilus influenzae in Queensland, Australia, 2002-2011: Young Indigenous children remain at highest risk. J Paediatr Child Health 2018; 54:36.</a></li><li><a class="nounderline abstract_t">Brown NE, Blain AE, Burzlaff K, et al. Racial Disparities in Invasive Haemophilus influenzae Disease-United States, 2008-2017. Clin Infect Dis 2021; 73:1617.</a></li><li><a class="nounderline abstract_t">Murphy TF. Haemophilus influenzae in chronic bronchitis. Semin Respir Infect 2000; 15:41.</a></li><li><a class="nounderline abstract_t">Collins S, Ramsay M, Slack MP, et al. Risk of invasive Haemophilus influenzae infection during pregnancy and association with adverse fetal outcomes. JAMA 2014; 311:1125.</a></li><li><a class="nounderline abstract_t">Cardines R, Giufrè M, Pompilio A, et al. Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int J Med Microbiol 2012; 302:45.</a></li><li><a class="nounderline abstract_t">Sriram KB, Cox AJ, Clancy RL, et al. Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians. Crit Rev Microbiol 2018; 44:125.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995. MMWR Morb Mortal Wkly Rep 1996; 45:901.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). Surveillance reports. Haemophilus influenzae. Available at: https://www.cdc.gov/abcs/reports-findings/surv-reports.html (Accessed on May 14, 2019).</li><li><a class="nounderline abstract_t">Briere EC, Jackson M, Shah SG, et al. Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009. Pediatrics 2012; 130:414.</a></li><li><a class="nounderline abstract_t">Kostman JR, Sherry BL, Fligner CL, et al. Invasive Haemophilus influenzae infections in older children and adults in Seattle. Clin Infect Dis 1993; 17:389.</a></li><li><a class="nounderline abstract_t">Li KI, Kiernan S, Wald ER, Reilly JS. Isolated uvulitis due to Haemophilus influenzae type b. Pediatrics 1984; 74:1054.</a></li><li><a class="nounderline abstract_t">Bozio CH, Blain A, Edge K, et al. Clinical Characteristics and Adverse Clinical Outcomes of Invasive Haemophilus influenzae Serotype a Cases-United States, 2011-2015. Clin Infect Dis 2021; 73:e3670.</a></li><li><a class="nounderline abstract_t">Bruce MG, Deeks SL, Zulz T, et al. Epidemiology of Haemophilus influenzae serotype a, North American Arctic, 2000-2005. Emerg Infect Dis 2008; 14:48.</a></li><li><a class="nounderline abstract_t">Adderson EE, Byington CL, Spencer L, et al. Invasive serotype a Haemophilus influenzae infections with a virulence genotype resembling Haemophilus influenzae type b: emerging pathogen in the vaccine era? Pediatrics 2001; 108:E18.</a></li><li><a class="nounderline abstract_t">Arnold CJ, Garrigues G, St Geme JW 3rd, Sexton DJ. Necrotizing fasciitis caused by Haemophilus influenzae serotype f. J Clin Microbiol 2014; 52:3471.</a></li><li><a class="nounderline abstract_t">Ali RA, Kaplan SL, Rosenfeld SB. Polyarticular Septic Arthritis Caused by Haemophilus influenzae Serotype f in an 8-Month-Old Immunocompetent Infant: A Case Report and Review of the Literature. Case Rep Orthop 2015; 2015:163812.</a></li><li><a class="nounderline abstract_t">Hoshino T, Hachisu Y, Kikuchi T, et al. Analysis of Haemophilus influenzae serotype f isolated from three Japanese children with invasive H. influenzae infection. J Med Microbiol 2015; 64:355.</a></li><li><a class="nounderline abstract_t">Farley MM, Stephens DS, Brachman PS Jr, et al. Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med 1992; 116:806.</a></li><li><a class="nounderline abstract_t">Quentin R, Musser JM, Mellouet M, et al. Typing of urogenital, maternal, and neonatal isolates of Haemophilus influenzae and Haemophilus parainfluenzae in correlation with clinical source of isolation and evidence for a genital specificity of H. influenzae biotype IV. J Clin Microbiol 1989; 27:2286.</a></li><li><a class="nounderline abstract_t">Harabuchi Y, Faden H, Yamanaka N, et al. Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. Tonawanda/Williamsville Pediatrics. J Infect Dis 1994; 170:862.</a></li><li><a class="nounderline abstract_t">Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.</a></li><li><a class="nounderline abstract_t">Porter M, Charles AK, Nathan EA, et al. Haemophilus influenzae: a potent perinatal pathogen disproportionately isolated from Indigenous women and their neonates. Aust N Z J Obstet Gynaecol 2016; 56:75.</a></li><li><a class="nounderline abstract_t">Hershckowitz S, Elisha MB, Fleisher-Sheffer V, et al. A cluster of early neonatal sepsis and pneumonia caused by nontypable Haemophilus influenzae. Pediatr Infect Dis J 2004; 23:1061.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Best practices for use of polymerase chain reaction (PCR) for diagnosing Haemophilus influenzae and Neisseria meningitidis disease and public health importance of identifying serotype/serogroup. Available at: https://www.cdc.gov/meningococcal/laboratory/pcr-guidance-mening-hflu.html (Accessed on May 14, 2019).</li><li><a class="nounderline abstract_t">Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:e1.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Best Practices for Use of Polymerase Chain Reaction (PCR) for Diagnosing Haemophilus influenzae and Neisseria meningitidis Disease and Public Health Importance of Identifying Serotype/Serogroup. https://www.cdc.gov/meningococcal/downloads/hi-nm-pcr-best-practices.pdf (Accessed on June 22, 2021).</li><li><a class="nounderline abstract_t">Heilmann KP, Rice CL, Miller AL, et al. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother 2005; 49:2561.</a></li><li><a class="nounderline abstract_t">Potts CC, Rodriguez-Rivera LD, Retchless AC, et al. Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016. Microbiol Spectr 2022; 10:e0257921.</a></li><li><a class="nounderline abstract_t">Han MS, Jung HJ, Lee HJ, Choi EH. Increasing Prevalence of Group III Penicillin-Binding Protein 3 Mutations Conferring High-Level Resistance to Beta-Lactams Among Nontypeable Haemophilus influenzae Isolates from Children in Korea. Microb Drug Resist 2019; 25:567.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012; 55 Suppl 3:S187.</a></li><li><a class="nounderline abstract_t">García-Cobos S, Campos J, Lázaro E, et al. Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother 2007; 51:2564.</a></li><li><a class="nounderline abstract_t">Honda H, Sato T, Shinagawa M, et al. Multiclonal Expansion and High Prevalence of β-Lactamase-Negative Haemophilus influenzae with High-Level Ampicillin Resistance in Japan and Susceptibility to Quinolones. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Shuel M, Hoang L, Law DK, Tsang R. Invasive Haemophilus influenzae in British Columbia: non-Hib and non-typeable strains causing disease in children and adults. Int J Infect Dis 2011; 15:e167.</a></li><li><a class="nounderline abstract_t">Nakamura S, Yanagihara K, Seki M, et al. Clinical characteristics of pneumonia caused by beta-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR). Scand J Infect Dis 2007; 39:521.</a></li><li><a class="nounderline abstract_t">Ohno A, Ishii Y, Kobayashi I, Yamaguchi K. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia. J Infect Chemother 2007; 13:296.</a></li><li><a class="nounderline abstract_t">Yanagihara K, Watanabe A, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: General view of the pathogens' antibacterial susceptibility. J Infect Chemother 2017; 23:587.</a></li><li><a class="nounderline abstract_t">Sakata H, Watanabe A, Iwata S, et al. Surveillance on susceptibility of strains isolated from pediatric infections. J Infect Chemother 2019; 25:163.</a></li><li><a class="nounderline abstract_t">Omoding D, Bazira J. Isolation and Antibiotic Susceptibility Testing of Haemophilus influenzae from Nasopharynx of Children under Five Years Attending Maternal and Child Health Clinic in Mbarara Regional Referral Hospital. Can J Infect Dis Med Microbiol 2019; 2019:6542919.</a></li><li><a class="nounderline abstract_t">Zhu H, Wang A, Tong J, et al. Nasopharyngeal carriage and antimicrobial susceptibility of Haemophilus influenzae among children younger than 5 years of age in Beijing, China. BMC Microbiol 2015; 15:6.</a></li><li><a class="nounderline abstract_t">Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35:S65.</a></li></ol></div><div id="topicVersionRevision">Topic 8048 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8106767" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evidence for capsule gene sequences among pharyngeal isolates of nontypeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8106767" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence for capsule gene sequences among pharyngeal isolates of nontypeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25976004" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genital carriage of the genus Haemophilus in pregnancy: species distribution and antibiotic susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018185" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vaginal flora as the source for neonatal early onset Haemophilus influenzae sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018185" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Vaginal flora as the source for neonatal early onset Haemophilus influenzae sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1588164" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of invasive Haemophilus influenzae type b disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/313003" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Haemophilus influenzae meningitis. A national study of secondary spread in household contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8145705" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. Recommendations of the advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368889" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevention of Hemophilus influenzae type b disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3874293" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Secondary Haemophilus influenzae type b in day-care facilities. Risk factors and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3497249" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Transmission of invasive Haemophilus influenzae type b disease in day care settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3491316" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The risk of subsequent transmission of Hemophilus influenzae type B disease among children in day care. Results of a two-year statewide prospective surveillance and contact survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3491319" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk of subsequent disease among day-care contacts of patients with systemic Hemophilus influenzae type B disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10234841" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9864255" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adhesin expression in matched nasopharyngeal and middle ear isolates of nontypeable Haemophilus influenzae from children with acute otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816486" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pilus-mediated adherence of Haemophilus influenzae to human respiratory mucins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9380466" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Insights into the mechanism of respiratory tract colonization by nontypable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304471" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Unraveling Haemophilus influenzae virulence mechanisms enable discovery of new targets for antimicrobials and vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985547" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High-density Bacterial Nasal Carriage in Children Is Transient and Associated With Respiratory Viral Infections-Implications for Transmission Dynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30455693" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23369277" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Haemophilus influenzae and the lung (Haemophilus and the lung).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4106658" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Human cell-surface structures related to Haemophilus influenzae type B disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6416146" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The IgA1 proteases of pathogenic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25995193" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Expression of IgA Proteases by Haemophilus influenzae in the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25995193" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Expression of IgA Proteases by Haemophilus influenzae in the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900515" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24218477" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Internalization and trafficking of nontypeable Haemophilus influenzae in human respiratory epithelial cells and roles of IgA1 proteases for optimal invasion and persistence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889047" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Infectious diseases associated with complement deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18803761" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Systemic humoral immunity to non-typeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8096561" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Population-based study of non-typable Haemophilus influenzae invasive disease in children and neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746530" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of age, breast feeding, and household structure on Haemophilus influenzae type b disease risk and antibody acquisition in Alaskan Eskimos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1588179" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The role of complement in the host's defense against Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11952636" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Molecular and cellular determinants of non-typeable Haemophilus influenzae adherence and invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057458" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nontypeable Haemophilus influenzae as a pathogen in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3258568" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3486923" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Epidemiology of colonization by nontypable Haemophilus influenzae in children: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2584370" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Turnover of nontypable Haemophilus influenzae in the nasopharynges of healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797903" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3812456" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Possible association of mycoplasma and viral respiratory infections with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8451094" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Preceding respiratory infection predisposing for primary and secondary invasive Haemophilus influenzae type b disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29121208" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dynamics of Bacterial Colonization With Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6332018" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Relative proportions of Haemophilus species in the throat of healthy children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346003" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21676359" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Haemophilus influenzae type b infection, vaccination, and H. influenzae carriage in children in Minnesota, 2008-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422439" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6600849" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889812" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Commentary: The Conquest of Haemophilus influenzae Type B-The Importance of Protecting High-Risk Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19748399" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29903376" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24572654" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24572654" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509834" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease-United States, 2009-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32589699" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Epidemiology of Invasive Haemophilus influenzae Serotype a Disease-United States, 2008-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20398617" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20178414" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Invasive Haemophilus influenzae disease in Utah children: an 11-year population-based study in the era of conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054663" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202421" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Invasive Haemophilus influenzae Disease, Europe, 1996-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12508153" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268829" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Haemophilus influenzae serotype a as a cause of serious invasive infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369218" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Emergence of Invasive Haemophilus influenzae Type A Disease in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22515912" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Invasive Haemophilus influenzae serotype e and f disease, England and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22080119" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860046" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Invasive Nontypeable Haemophilus influenzae Infection Among Adults With HIV in Metropolitan Atlanta, Georgia, 2008-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407156" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Invasive Disease Caused by Nontypeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29200182" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Invasive Haemophilus Influenzae Type B Infections in Children with Cancer in the Era of Infant HIB Immunization Programs (1991-2014): A Report From the Canadian Immunization Monitoring Program Active.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19761408" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Invasive Haemophilus influenzae disease caused by non-type b strains in Northwestern Ontario, Canada, 2002-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28871608" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Paediatric invasive Haemophilus influenzae in Queensland, Australia, 2002-2011: Young Indigenous children remain at highest risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33993217" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Racial Disparities in Invasive Haemophilus influenzae Disease-United States, 2008-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749549" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Haemophilus influenzae in chronic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24643602" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Risk of invasive Haemophilus influenzae infection during pregnancy and association with adverse fetal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001303" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28539074" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8927012" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8927012" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869828" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8218679" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Invasive Haemophilus influenzae infections in older children and adults in Seattle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6334271" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Isolated uvulitis due to Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32668450" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical Characteristics and Adverse Clinical Outcomes of Invasive Haemophilus influenzae Serotype a Cases-United States, 2011-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258076" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Epidemiology of Haemophilus influenzae serotype a, North American Arctic, 2000-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11433097" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Invasive serotype a Haemophilus influenzae infections with a virulence genotype resembling Haemophilus influenzae type b: emerging pathogen in the vaccine era?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989609" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Necrotizing fasciitis caused by Haemophilus influenzae serotype f.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26064739" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Polyarticular Septic Arthritis Caused by Haemophilus influenzae Serotype f in an 8-Month-Old Immunocompetent Infant: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25657301" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Analysis of Haemophilus influenzae serotype f isolated from three Japanese children with invasive H. influenzae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314530" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2584379" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Typing of urogenital, maternal, and neonatal isolates of Haemophilus influenzae and Haemophilus parainfluenzae in correlation with clinical source of isolation and evidence for a genital specificity of H. influenzae biotype IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7930728" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. Tonawanda/Williamsville Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26503452" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Haemophilus influenzae: a potent perinatal pathogen disproportionately isolated from Indigenous women and their neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545867" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A cluster of early neonatal sepsis and pneumonia caused by nontypable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545867" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A cluster of early neonatal sepsis and pneumonia caused by nontypable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955859" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955859" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917574" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35536039" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484742" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Increasing Prevalence of Group III Penicillin-Binding Protein 3 Mutations Conferring High-Level Resistance to Beta-Lactams Among Nontypeable Haemophilus influenzae Isolates from Children in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903951" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470649" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29987153" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Multiclonal Expansion and High Prevalence ofβ-Lactamase-Negative Haemophilus influenzae with High-Level Ampicillin Resistance in Japan and Susceptibility to Quinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134777" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Invasive Haemophilus influenzae in British Columbia: non-Hib and non-typeable strains causing disease in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577813" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical characteristics of pneumonia caused by beta-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17982717" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669567" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: General view of the pathogens' antibacterial susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30600131" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Surveillance on susceptibility of strains isolated from pediatric infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944683" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Isolation and Antibiotic Susceptibility Testing of Haemophilus influenzae from Nasopharynx of Children under Five Years Attending Maternal and Child Health Clinic in Mbarara Regional Referral Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25648185" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Nasopharyngeal carriage and antimicrobial susceptibility of Haemophilus influenzae among children younger than 5 years of age in Beijing, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068815" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
